VANCOUVER, BC / ACCESSWIRE / March 16, 2017 / CVR Medical Corp. (TSX.V:CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) announces partnership with ADCO Circuits, a Michigan-based electronic design and manufacturing company. ADCO will be the exclusive provider of the custom circuit board inside the sensor of CVR’s “Carotid Stenotic Scan (CSS)” device.
ADCO Circuits is a certified ISO 9002, ISO AS9100, and ISO TS16949 manufacturer of electronic assemblies and full system box builds. With over 35 years of experience, they are recognized as industry leaders capable of managing projects from prototype to volume production. Their involvement with CVR ensures quality and reliability for one of the vital components in the testing module of the CSS. ADCO’s state-of-the-art manufacturing facility, located in Rochester Hills, MI, allows for maximum efficiency in the full-scaled production process CVR will require. CVR Global COO Tony Robinson states, “Our work with ADCO has been an integral part of creating such a technically sound device. We’re proud of that, and it is indicative of the incredible reputation they’ve developed and earned.”
On their work on the CSS, ADCO Executive Officer Marc Damman states, “We’ve been looking forward to seeing this project through to its launch, and being alongside CVR in the future as they expand beyond this product. They’ve created game-changing technology, and we’re excited to be a part of it.”
For additional information on the organization, leadership, and current news please visit the company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM. 2
ON BEHALF OF THE BOARD:
(signed) “Peter Bakema”
CEO, President & Director
For further information contact:
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.